These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32233322)

  • 1. [Hypereosinophilic syndromes].
    Groh M; Lefèvre G; Ackermann F; Étienne N; Kahn JE
    Rev Prat; 2019 Sep; 69(7):767-773. PubMed ID: 32233322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Hypereosinophilic Syndromes in Childhood].
    Leu T; Simon HU; Hebestreit H; Kunzmann S
    Klin Padiatr; 2015 Nov; 227(6-7):308-13. PubMed ID: 26267413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib for the treatment of hypereosinophilic syndromes.
    Helbig G
    Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
    Kuang FL; Klion AD
    J Allergy Clin Immunol Pract; 2017; 5(6):1502-1509. PubMed ID: 29122152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
    Helbig G; Kyrcz-Krzemień S
    Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hypereosinophilic syndromes: current concepts and treatments.
    Gleich GJ; Leiferman KM
    Br J Haematol; 2009 May; 145(3):271-85. PubMed ID: 19243381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Hypereosinophilic Syndromes.
    Roufosse F
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):561-75. PubMed ID: 26209900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
    Williams AK; Dou C; Chen LYC
    Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypereosinophilic syndromes: pathogenic and therapeutic up-to-date].
    Kahn JE; Grandpeix-Guyodo C; Ackermann F; Charles P; Legrand F; Blétry O
    Rev Med Interne; 2010 Apr; 31(4):268-76. PubMed ID: 20303627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
    Borbényi Z
    Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
    Coutré S; Gotlib J
    Semin Cancer Biol; 2004 Feb; 14(1):23-31. PubMed ID: 14757533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies).
    Iurlo A; Cattaneo D; Gianelli U
    Expert Rev Hematol; 2019 Dec; 12(12):1077-1088. PubMed ID: 31588817
    [No Abstract]   [Full Text] [Related]  

  • 18. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.
    Coutré S; Gotlib J
    Semin Cancer Biol; 2004 Aug; 14(4):307-15. PubMed ID: 15305431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.